Funder: National Institutes of Health

Due Dates: May 7, 2025 (AIDS) | Jan 7, 2026 (AIDS) | May 7, 2026 (AIDS) | Jan 7, 2027 (AIDS) | May 7, 2027 (AIDS) | Jan 7, 2028 (AIDS) | May 7, 2028 (AIDS) | Sep 7, 2028 (AIDS) | Jan 7, 2029 (AIDS)

Funding Amounts: Up to $400,000 direct costs per year, for a maximum of 4 years (R01 mechanism).

Summary: Supports research to elucidate mechanisms of early immune system development from in utero through adolescence, with emphasis on HIV/ART exposure and immune ontogeny.

Key Information: Clinical trials are optional; foreign and domestic institutions are eligible; contact NIH if requesting ≥$500,000 direct costs in any year.